Ibudilast in multiple sclerosis

Ibudilast, which targets IL-1beta, TNF-alpha and IL-6, has shown beneficial effects on various imaging findings in progressive multiple sclerosis. In this Phase II clinical trial, researchers evaluated the benefit of this treatment on the evolution of certain MS neurological lesions over a 96-week period. A total of 195 patients with progressive MS were followed at 28 different sites, and randomized to ibudilast or placebo. Ibudilast improved patients' MRI findings at two levels, suggesting a neuroprotective effect of this new treatment in progressive MS.